Conferences - Results from #260

Viewing 261-280 of 11114 articles

ASCO GU 2024: Evaluating Prognostic Models for Stage I Seminoma Within the Randomised Trial of Imaging and Surveillance in Seminoma Testis (TRISST)

ASCO GU 2024: Cabozantinib plus Atezolizumab in Locally Advanced/metastatic Adrenocortical Carcinoma: Results from a Multi-Cohort Basket Phase II Trial, CABATEN/GETNE-T1914

ASCO GU 2024: Survivorship Issues Beyond 2 Years After Treatment in Testicular Germ Cell Tumors: Experience from a Large Center in the United Kingdom

ASCO GU 2024: The Impact of Immunotherapy-Based Regimens in Primary Renal Tumors

ASCO GU 2024: First-line Pembrolizumab plus Lenvatinib for Non–clear Cell RCC: Extended Follow-up of the Phase 2 KEYNOTE-B61 Study

ASCO GU 2024: The Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era of Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis of 2319 Patients

ASCO GU 2024: Evaluating Intermediate Endpoints for Overall Survival in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors: An IMDC Study

ASCO GU 2024: Discussant: Adjuvant Treatment for RCC – Strategies on How to Optimize Patient Selection for The New Standard of Care

ASCO GU 2024: AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma Versus Observation (Late-Breaking Abstract)

ASCO GU 2024: Predicting Clinical Outcomes in the S1314-COXEN Trial Using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression

ASCO GU 2024: Adjuvant Nivolumab Monotherapy vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results from Part B of the Randomized, Phase 3 CheckMate 914 Trial

ASCO GU 2024: Overall Survival Results from the Phase 3 KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell RCC

ASCO GU 2024: Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma (PemCab)

ASCO GU 2024: Avelumab First-Line Maintenance Therapy for Locally Advanced/metastatic Urothelial Carcinoma: Results from the Real-World US PATRIOT-II Study

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

ASCO GU 2024: GDFather-Neo - Neutralizing GDF-15 in MIBC: A Neoadjuvant Immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab

ASCO GU 2024: Enfortumab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma: Subgroup Analyses Results from EV-302, a Phase 3 Global Study

ASCO GU 2024: INVEST: A Phase Ib Window of Opportunity Study of Atezolizumab Administered Either Intravesically or Direct Tumor Injection in Patients with Bladder Cancer Prior to Radical Cystectomy

ASCO GU 2024: Sequential Endoluminal Gemcitabine and Docetaxel vs BCG for the Treatment of High-grade UTUC

ASCO GU 2024: First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Followed by Postsurgical Adjuvant Nivolumab in Patients with MIBC

9
10
11
12
13
14
15
16
17
18